Oncogenic Ras in tumour progression and metastasis

被引：222

作者：

Giehl, K ^{[1
]}

机构：

[1] Univ Ulm, Dept Pharmacol & Toxicol, D-89069 Ulm, Germany

来源：

BIOLOGICAL CHEMISTRY | 2005年 / 386卷 / 03期

关键词：

extracellular signal-regulated kinase (ERK); migration; phosphatidylinositol 3-kinase (PI3-K); Rho GTPases; signal transduction; transformation;

D O I：

10.1515/BC.2005.025

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The ras genes give rise to a family of related GTP-binding proteins that exhibit potent transforming potential. Mutational activation of Ras proteins promotes oncogenesis by disturbing a multitude of cellular processes, such as gene expression, cell cycle progression and cell proliferation, as well as cell survival, and cell migration. Ras signalling pathways are well known for their involvement in tumour initiation, but less is known about their contribution to invasion and metastasis. This review summarises the role and mechanisms of Ras signalling, especially the role of the Ras effector cascade Raf/MEK/ ERK, as well as the phosphatidylinositol 3-kinase/Akt pathway in Ras-mediated transformation and tumour progression. In addition, it discusses the impact of Rho GTPases on Ras-mediated transformation and metastasis.

引用

页码：193 / 205

页数：13

共 172 条

[1] Blocking oncogenic Ras signaling for cancer therapy [J].

Adjei, AA .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (14) :1062-1074

[2] Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma [J].

Aguirre, AJ ;

Bardeesy, N ;

Sinha, M ;

Lopez, L ;

Tuveson, DA ;

Horner, J ;

Redston, MS ;

DePinho, RA .

GENES & DEVELOPMENT, 2003, 17 (24) :3112-3126

[3] Direct integrin αvβ6-ERK binding:: implications for tumour growth [J].

Ahmed, N ;

Niu, J ;

Dorahy, DJ ;

Gu, XH ;

Andrews, S ;

Meldrum, CJ ;

Scott, RJ ;

Baker, MS ;

Macreadie, IG ;

Agrez, MV .

ONCOGENE, 2002, 21 (09) :1370-1380

[4] Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: A north central cancer treatment group phase II trial [J].

Alberts, SR ;

Schroeder, M ;

Erlichman, C ;

Steen, PD ;

Foster, NR ;

Moore, DF ;

Rowland, KM ;

Nair, S ;

Tschetter, LK ;

Fitch, TR .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (24) :4944-4950

[5] MOST HUMAN CARCINOMAS OF THE EXOCRINE PANCREAS CONTAIN MUTANT C-K-RAS GENES [J].

ALMOGUERA, C ;

SHIBATA, D ;

FORRESTER, K ;

MARTIN, J ;

ARNHEIM, N ;

PERUCHO, M .

CELL, 1988, 53 (04) :549-554

[6]

AOKI K, 1995, CANCER RES, V55, P3810

[7]

Aoki K, 1997, MOL CARCINOGEN, V20, P251, DOI 10.1002/(SICI)1098-2744(199710)20:2<251::AID-MC12>3.3.CO

[8]

2-P

[9] H-ras but not K-ras traffics to the plasma membrane through the exocytic pathway [J].

Apolloni, A ;

Prior, IA ;

Lindsay, M ;

Parton, RG ;

Hancock, JF .

MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (07) :2475-2487

[10] Ras and Rho GTPases: A family reunion [J].

Bar-Sagi, D ;

Hall, A .

CELL, 2000, 103 (02) :227-238

← 1 2 3 4 5 6 7 8 9 10 →